Roots Analysis

OCTOBER 30, 2023

The next generation RNA therapeutics and RNA vaccines pipeline currently features the presence of more than 20 circular RNA therapeutics and vaccines, being developed across initial stages of drug development (discovery and preclinical).

Vaccines 40

Vaccines Immunization Packaging Pharmaceutical Companies 40

pharmaphorum

JANUARY 27, 2023

The same goes for many commodities used in the production process for key medicines, from solvents through to packaging. The recent reversal of China’s “zero Covid” policy, at a time when the country still lacks optimal vaccine coverage, has also created another unknown, in terms of global supply and demand forecasting.

Packaging 105

Packaging Vaccines 105

European Pharmaceutical Review

MARCH 11, 2024

Additionally, this can be caused by “poor handling, repackaging, and nonadherence to good manufacturing practices [GMP] during dispensing and packaging have resulted in the microbiological contamination of non-sterile pharmaceutical products.” Ahmed et al.

Sterile Compounds 98

Sterile Compounds Compounding Packaging Pharmaceutical Companies 98

European Pharmaceutical Review

DECEMBER 26, 2023

Advanced inducible systems to better regulate the expression of certain genes will improve the generation of packaging and producer cell clones, giving companies more control over gene expression for improved safety as well as efficiency. Single-use bioprocessing technologies enabling more rapid vaccines production [Internet].

Packaging 98

Packaging Vaccines 98

ISPE

MARCH 8, 2023

The cases covered the same types of contaminants and impurities noted in Table 1: microbial contaminants, process-related im-purities, metal contaminants, packaging-related contaminants, drug cross-contamination, and an “unknown” category encompassing other contaminants associated with the manufacturing process, including those from cell culturing.

Compounding 52

Compounding Compounding Pharmacies Packaging FDA 52